

Hepatocellular carcinoma: ESMO Clinical Practice Guid follow-up

Annals of Oncology

29, iv238-iv255

DOI: [10.1093/annonc/mdy308](https://doi.org/10.1093/annonc/mdy308)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. <i>Nutrients</i> , 2018, 10, 1756.	1.7	178
2	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 872-884.	1.9	31
3	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. <i>Cancers</i> , 2019, 11, 1116.	1.7	17
4	Biomarkers <i>vs</i> imaging in the early detection of hepatocellular carcinoma and prognosis. <i>World Journal of Clinical Cases</i> , 2019, 7, 1367-1382.	0.3	15
5	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1151.	1.7	21
6	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 721-730.	3.7	105
7	Treatment Lines in Hepatocellular Carcinoma. <i>Visceral Medicine</i> , 2019, 35, 266-272.	0.5	31
8	Interventional Oncology: A new pillar for a comprehensive cancer care. <i>Presse Medicale</i> , 2019, 48, e217-e218.	0.8	4
9	Percutaneous image-guided therapies of primary liver tumors: Techniques and outcomes. <i>Presse Medicale</i> , 2019, 48, e245-e250.	0.8	2
10	Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 41.	7.1	150
11	Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1077-1088.	1.4	5
12	Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 812-821.	0.9	17
13	Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. <i>Brachytherapy</i> , 2019, 18, 823-828.	0.2	23
14	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 23-30.	1.8	16
15	Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 1395-1397.	0.6	35
16	Molecular and histological correlations in liver cancer. <i>Journal of Hepatology</i> , 2019, 71, 616-630.	1.8	308
17	Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. <i>Frontiers in Pharmacology</i> , 2019, 10, 450.	1.6	26
18	Human Liver Regeneration: An Etiology Dependent Process. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2332.	1.8	31

#	ARTICLE	IF	CITATIONS
19	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules in cirrhosis. <i>Liver International</i> , 2019, 39, 1281-1291.	1.9	20
20	Lenvatinib: A Review in Hepatocellular Carcinoma. <i>Drugs</i> , 2019, 79, 665-674.	4.9	159
21	Combination of radiofrequency ablation and transcatheter arterial chemoembolization to treat hepatocellular carcinoma: measurement of distance from needle tip to nodule for assessment of local tumor progression. <i>Journal of International Medical Research</i> , 2019, 47, 2516-2523.	0.4	2
22	Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization. <i>EJNMMI Research</i> , 2019, 9, 19.	1.1	21
23	Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. <i>Theranostics</i> , 2019, 9, 1426-1452.	4.6	53
24	Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 616-617.	1.9	0
25	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 17-29.	2.6	45
26	Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1468-1477.	1.9	86
27	Programmed cell death protein 1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	1.9	106
28	Downregulation of nucleolar and spindle-associated protein 1 expression suppresses liver cancer cell function. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 2969-2978.	0.8	8
29	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. <i>Targeted Oncology</i> , 2019, 14, 115-123.	1.7	19
30	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1110-1111, 116-123.	1.2	9
31	YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. <i>International Journal of Molecular Sciences</i> , 2019, 20, 638.	1.8	44
32	Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2019, 14, 107-113.	1.7	21
33	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <i>BMJ Open</i> , 2019, 9, e031434.	0.8	27
36	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. <i>The Cochrane Library</i> , 2019, , .	1.5	5
37	Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study. <i>EBioMedicine</i> , 2019, 50, 156-165.	2.7	131
38	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129

#	ARTICLE	IF	CITATIONS
39	History and development of radioembolization. <i>Nuclear Medicine Communications</i> , 2019, 40, 684-692.	0.5	4
40	Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988900.	1.4	6
41	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	0.6	2
42	Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward. <i>Hepatology</i> , 2019, 70, 446-447.	3.6	5
43	Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 230-238.	0.9	13
44	Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 75-84.	1.8	105
45	International trends in hepatocellular carcinoma incidence, 1978-2012. <i>International Journal of Cancer</i> , 2020, 147, 317-330.	2.3	303
46	Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2020, 11, 557-565.	0.5	5
47	Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. <i>Oncologist</i> , 2020, 25, e1274-e1279.	1.9	11
50	Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. <i>European Journal of Radiology</i> , 2020, 124, 108806.	1.2	13
51	Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 1349-1364.	1.3	30
52	Is laparoscopic liver resection suitable for selected patients with BCLC stage B HCC? A propensity score-matched analysis. <i>Hpb</i> , 2020, 22, 595-602.	0.1	5
53	Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. <i>Future Oncology</i> , 2020, 16, 4315-4325.	1.1	18
54	Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101946.	3.4	104
55	Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. <i>Abdominal Radiology</i> , 2020, 45, 3326-3336.	1.0	4
56	Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. <i>Genes and Diseases</i> , 2020, 7, 370-379.	1.5	76
57	MR Imaging Enables Real-Time Monitoring of In Vitro Electrolytic Ablation of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 352-361.	0.2	3
58	Biodistribution and biocompatibility of glycyrrhetic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma. <i>Nanomedicine</i> , 2020, 15, 145-161.	1.7	21

#	ARTICLE	IF	CITATIONS
59	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. <i>Frontiers in Immunology</i> , 2020, 11, 568759.	2.2	79
60	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188451.	3.3	36
61	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.	1.7	55
62	LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma. <i>Genes and Diseases</i> , 2022, 9, 151-164.	1.5	8
63	The Changing Global Epidemiology of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 535-547.	1.0	41
64	Cured giant hepatocellular carcinoma after transarterial embolization complicated with liver abscess formation. <i>Radiology Case Reports</i> , 2020, 15, 1485-1492.	0.2	1
65	MiR-660-5p promotes the progression of hepatocellular carcinoma by interaction with YWHAH via PI3K/Akt signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 480-489.	1.0	16
67	Laparoscopic Liver Resection for Hepatocellular Carcinoma in Childâ€™Pugh A Patients With and Without Portal Hypertension: A Multicentre Study. <i>World Journal of Surgery</i> , 2020, 44, 3915-3922.	0.8	14
68	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47
69	Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. <i>The Cochrane Library</i> , 2020, , .	1.5	0
70	Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1639.	1.3	22
71	Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study. <i>Frontiers in Oncology</i> , 2020, 10, 578633.	1.3	13
72	Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 549-565.	1.7	12
73	Effectiveness and Safety of Nivolumab in Childâ€™Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. <i>Cancers</i> , 2020, 12, 1968.	1.7	40
74	Epidemiologic, humanistic, and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. <i>Hepatic Oncology</i> , 2020, 7, HEP27.	4.2	40
75	Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. <i>JHEP Reports</i> , 2020, 2, 100173.	2.6	24
76	Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. <i>Clinical Drug Investigation</i> , 2020, 40, 1167-1176.	1.1	14
77	Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570958.	1.3	8

#	ARTICLE	IF	CITATIONS
78	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
79	Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. <i>Clinical and Translational Imaging</i> , 2020, 8, 377-392.	1.1	0
80	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527.	1.7	21
81	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1581-1590.	0.8	4
82	Current Locoregional Therapies and Treatment Strategies in Hepatocellular Carcinoma. <i>Current Oncology</i> , 2020, 27, 144-151.	0.9	12
83	Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. <i>Current Oncology</i> , 2020, 27, 152-164.	0.9	14
84	Prognostic effect of systemic inflammation in patients undergoing surgery for hepatocellular carcinoma: comparison of composite ratios and cumulative scores. <i>Translational Cancer Research</i> , 2020, 9, 6154-6165.	0.4	4
85	Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study. <i>Frontiers in Oncology</i> , 2020, 10, 562103.	1.3	12
86	Costâ€“utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1055-1068.	1.1	6
87	Management of patients with intermediate stage hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097084.	1.4	25
88	Multi-modal and sequential treatment of liver cancer and its impact on the gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101709.	1.0	2
90	Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1672-1677.	1.0	6
91	Stereotactic body radiotherapy for hepatocellular carcinoma â€“ still searching for a role. <i>Journal of Hepatology</i> , 2020, 73, 15-16.	1.8	6
92	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. <i>Advances in Therapy</i> , 2020, 37, 2678-2695.	1.3	37
93	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	1.9	17
94	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma â€“ a substudy of the SORAMIC trial. <i>Acta OncolÃ³gica</i> , 2020, 59, 1028-1035.	0.8	11
95	A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 4589-4596.	1.2	11
96	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 808-820.	5.1	371

#	ARTICLE	IF	CITATIONS
97	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Review of Clinical Pharmacology, 2020, 13, 623-629.	1.3	8
98	Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma. Clinical and Translational Medicine, 2020, 10, e102.	1.7	50
99	Development and Validation of Pre- and Post-Operative Models to Predict Recurrence After Resection of Solitary Hepatocellular Carcinoma: A Multi-Institutional Study. Cancer Management and Research, 2020, Volume 12, 3503-3512.	0.9	4
100	Adherence and quality are key for a beneficial HCC surveillance. Liver International, 2020, 40, 751-753.	1.9	2
101	Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdominal Radiology, 2020, 45, 3119-3128.	1.0	9
102	The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. Cardiovascular and Interventional Radiology, 2020, 43, 1165-1172.	0.9	6
103	Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition. Cancers, 2020, 12, 615.	1.7	10
104	Reply to: "Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors". Journal of Hepatology, 2020, 72, 1033-1034.	1.8	0
105	Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. Cancer Control, 2020, 27, 107327482093584.	0.7	6
106	Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification. Cancer Imaging, 2020, 20, 42.	1.2	6
107	HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice. OncoTargets and Therapy, 2020, Volume 13, 5575-5588.	1.0	15
108	Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs, 2020, 80, 315-322.	4.9	38
109	Case Report of Synchronous Prostate, Hepatocellular, and Rectal Carcinomas and Review of the Literature. Case Reports in Surgery, 2020, 2020, 1-7.	0.2	0
110	Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. Oncology Research and Treatment, 2020, 43, 211-220.	0.8	20
111	Hepatic Resection Is Associated With Improved Long-Term Survival Compared to Radio-Frequency Ablation in Patients With Multifocal Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 110.	1.3	8
112	Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?. Journal of Hepatology, 2020, 72, 607-609.	1.8	4
113	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Annals of Oncology, 2020, 31, 334-351.	0.6	138
114	Paraplegia following transarterial chemoembolisation for hepatocellular carcinoma: a case report. Acta Chirurgica Belgica, 2021, 121, 437-440.	0.2	1

#	ARTICLE	IF	CITATIONS
115	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	1.9	26
116	Performance of a New Blunt-Tip Needle for the Displacement of Critical Structure in Thermal Ablation. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 924-930.	0.9	2
117	Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90. <i>Journal of Hepatology</i> , 2020, 72, 1046-1048.	1.8	4
118	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. <i>Radiotherapy and Oncology</i> , 2020, 148, 73-81.	0.3	23
119	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 194-200.	0.3	43
120	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	0.5	6
121	Morphophenotypic Classification of Hepatocellular Carcinoma: the Biliary/Stem Cell Subgroup and Worst Outcome—Implications on Patient Selection. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 698-707.	0.9	1
122	Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101464.	0.7	9
123	The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 50-62.	0.9	18
124	Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention. <i>Clinical Radiology</i> , 2021, 76, 160.e27-160.e33.	0.5	0
125	Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models. <i>European Radiology</i> , 2021, 31, 4367-4376.	2.3	18
126	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
127	The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 76, 453-458.	0.9	12
128	Therapeutic Ultrasound Parameter Optimization for Drug Delivery Applied to a Murine Model of Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 309-322.	0.7	10
129	Milestones in the treatment of hepatocellular carcinoma: A systematic review.. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103179.	2.0	14
130	Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1518-1528.	1.4	2
131	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1237-1251.	1.1	31
132	Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 75-86.	0.8	18

#	ARTICLE	IF	CITATIONS
133	Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 28-33.	0.6	5
134	A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 341-349.	1.1	6
135	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 36-49.	0.9	15
136	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2021, 113, 123-136.	3.0	28
137	Impact of anesthesia methods on perioperative systemic inflammation and long-term outcomes in patients undergoing surgery for hepatocellular carcinoma: a propensity score-matched analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 49-49.	0.7	4
138	⁶⁸ Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1235-1241.	2.8	39
139	Interventional Image-Guided HDR Brachytherapy as a Salvage Treatment: Exclusive or in Combination with Other Local Therapies. , 2021, , 201-217.		0
140	HepatozellulÄres Karzinom. , 2021, , 447-454.		0
141	3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. <i>Anti-Cancer Drugs</i> , 2021, 32, 386-393.	0.7	12
142	Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components. <i>Molecular Biology Reports</i> , 2021, 48, 551-562.	1.0	3
143	Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1095-1117.	2.3	21
144	Liver Function Changes After Technetium-99m-Macroaggregated Albumin Administration and Their Predictive Value Regarding Hepatotoxicity in Patients Undergoing Yttrium-90-Radioembolization. <i>Anticancer Research</i> , 2021, 41, 437-444.	0.5	1
145	MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2057-2068.	1.2	18
146	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. , 2021, 5, 304-322.		2
147	One- versus two-stage partial hepatectomy for large resectable solitary hepatocellular carcinomas determined preoperatively to have a narrow resection margin: a propensity score matching analysis. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 662-674.	0.7	1
148	Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Childâ€Pugh Class: A Nationwide Cohort Analysis in South Korea. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	2
149	Hepatocellular carcinoma in non-alcoholic fatty liver diseaseâ€”a review of an emerging challenge facing clinicians. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 59-75.	0.7	34
150	Patterns, timing, and predictors of recurrence after laparoscopic liver resection for hepatocellular carcinoma: results from a high-volume HPB center. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 1215-1223.	1.3	11

#	ARTICLE	IF	CITATIONS
151	The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	0.8	9
152	Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. <i>Annals of Translational Medicine</i> , 2021, 9, 237-237.	0.7	8
153	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. <i>Journal of Clinical Medicine</i> , 2021, 10, 903.	1.0	9
154	AI-Based Radiological Imaging for HCC: Current Status and Future of Ultrasound. <i>Diagnostics</i> , 2021, 11, 292.	1.3	11
155	Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 587554.	1.3	34
156	Identifying SLC27A5 as a potential prognostic marker of hepatocellular carcinoma by weighted gene co-expression network analysis and in vitro assays. <i>Cancer Cell International</i> , 2021, 21, 174.	1.8	10
157	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCG, GERCOR, UNICANCER, SFCG, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101590.	0.7	17
158	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 655697.	2.2	126
159	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	2.8	43
160	Clinical effects and prognosis of stereotactic body radiotherapy combined with transarterial chemoembolization for massive hepatocellular carcinoma. <i>Precision Radiation Oncology</i> , 2021, 5, 12-17.	0.4	0
161	Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy. <i>EJNMMI Research</i> , 2021, 11, 24.	1.1	6
162	Immunomodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. <i>Cancers</i> , 2021, 13, 1558.	1.7	8
163	Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3673-3683.	1.2	2
164	Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis. <i>Cancers</i> , 2021, 13, 1371.	1.7	10
165	External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. <i>Journal of Liver Cancer</i> , 2021, 21, 25-33.	0.3	5
166	How to Treat Hepatocellular Carcinoma in Elderly Patients. <i>Pharmaceuticals</i> , 2021, 14, 233.	1.7	9
167	Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0247958.	1.1	7
168	Aberrant protein glycosylation in cancer: implications in targeted therapy. <i>Biochemical Society Transactions</i> , 2021, 49, 843-854.	1.6	16

#	ARTICLE	IF	CITATIONS
169	Feasibility of SBRT for hepatocellular carcinoma in Brazil – a prospective pilot study. Reports of Practical Oncology and Radiotherapy, 2021, 26, 226-236.	0.3	1
170	Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing. Pharmaceuticals, 2021, 14, 389.	1.7	6
171	Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. Frontiers in Pharmacology, 2021, 12, 634084.	1.6	13
172	Imaging features and outcomes in patients with ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization: a retrospective clinical study. Journal of International Medical Research, 2021, 49, 030006052110077.	0.4	1
173	Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. Radiation Oncology, 2021, 16, 79.	1.2	13
174	Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543.	8.2	609
175	Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≤ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Advances in Therapy, 2021, 38, 2472-2490.	1.1	9
176	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	4.2	29
177	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Current Opinion in Oncology, 2021, 33, 386-394.	1.1	13
178	Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. Frontiers in Pharmacology, 2021, 12, 634087.	1.6	13
179	An excellent nomogram predicts microvascular invasion that cannot independently stratify outcomes of small hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 757-757.	0.7	4
181	Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. Cancers, 2021, 13, 2708.	1.7	19
182	Biomarkers for hepatocellular carcinoma based on body fluids and feces. World Journal of Gastrointestinal Oncology, 2021, 13, 351-365.	0.8	11
183	The Prognostic Correlation of Heart Rate Variability at Diagnosis with Survival of Patients with Hepatocellular Carcinoma. Diagnostics, 2021, 11, 890.	1.3	5
184	Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Bioscience Reports, 2021, 41, .	1.1	39
185	Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiation Oncology, 2021, 16, 86.	1.2	11
186	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina Clínica (English Edition), 2021, 156, 463.e1-463.e30.	0.1	16
187	Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World Journal of Gastroenterology, 2021, 27, 2415-2433.	1.4	16

#	ARTICLE	IF	CITATIONS
188	The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101664.	0.7	9
189	Six application scenarios of artificial intelligence in the precise diagnosis and treatment of liver cancer. <i>Artificial Intelligence Review</i> , 2021, 54, 5307-5346.	9.7	11
190	Hepatocellular carcinoma: a clinical and pathological overview. <i>Pathologica</i> , 2021, 113, 203-217.	1.3	30
191	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	1.3	5
192	Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2022, 40, 458-467.	0.8	4
193	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. <i>Digestive Diseases</i> , 2022, 40, 322-334.	0.8	3
194	Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. <i>ESMO Open</i> , 2021, 6, 100129.	2.0	6
195	Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 545-563.	1.8	26
197	An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. <i>Annals of Translational Medicine</i> , 2021, 9, 1004-1004.	0.7	4
198	Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. <i>Quality of Life Research</i> , 2022, 31, 473-485.	1.5	10
199	Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. <i>Radiology and Oncology</i> , 2021, 55, 247-258.	0.6	17
200	Choledocho-nodal Fistula: Uncommon Cause of Obstructive Jaundice in a Patient with HCC Diagnosed by Combined ERCP/EUS. <i>Journal of Clinical Imaging Science</i> , 2021, 11, 32.	0.4	0
201	Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0252678.	1.1	2
202	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021, 32, 801-805.	0.6	235
203	The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation. <i>Medicine (United States)</i> , 2021, 100, e26487.	0.4	2
204	Prediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk Models. <i>Annals of Surgical Oncology</i> , 2021, 28, 8211-8220.	0.7	6
205	Validation of the collapsed cone algorithm for HDR liver brachytherapy against Monte Carlo simulations. <i>Brachytherapy</i> , 2021, 20, 936-947.	0.2	1
206	The immunological and metabolic landscape in primary and metastatic liver cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 541-557.	12.8	212

#	ARTICLE	IF	CITATIONS
207	Percutaneous microwave ablation versus robot-assisted hepatectomy for early hepatocellular carcinoma: A real-world single-center study. <i>Digestive and Liver Disease</i> , 2022, 54, 243-250.	0.4	2
208	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1909.	1.8	6
209	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101766.	0.7	0
210	Radioembolization for Hepatocellular Carcinoma. <i>Digestive Disease Interventions</i> , 2021, 05, 268-276.	0.3	0
211	The Therapeutic Effect of Myrrh (<i>Commiphora molmol</i>) and Doxorubicin on Diethylnitrosamine Induced Hepatocarcinogenesis in Male Albino Rats. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2153-2163.	0.5	8
212	Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. <i>Cancer</i> , 2021, 127, 3782-3793.	2.0	82
213	HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p. <i>Anti-Cancer Drugs</i> , 2022, 33, e273-e285.	0.7	11
214	Cancer and hepatic steatosis. <i>ESMO Open</i> , 2021, 6, 100185.	2.0	9
215	Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26958.	0.4	3
216	Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 956-968.	0.9	12
217	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1159-1167.	1.4	6
218	Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 667641.	2.0	1
219	Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. <i>Biomarker Research</i> , 2021, 9, 64.	2.8	13
220	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 434-442.	0.7	28
221	Long-Term Outcomes of Personalized Stereotactic Ablative Brachytherapy for Recurrent Head and Neck Adenoid Cystic Carcinoma after Surgery or External Beam Radiotherapy: A 9-Year Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 839.	1.1	8
222	Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study. <i>Disease Markers</i> , 2021, 2021, 1-11.	0.6	0
223	A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su TM) Target Area Delineation. <i>Frontiers in Oncology</i> , 2021, 11, 680303.	1.3	6
224	Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. <i>Oncologist</i> , 2021, 26, 854-864.	1.9	16

#	ARTICLE	IF	CITATIONS
225	Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. <i>European Radiology</i> , 2022, 32, 1320-1329.	2.3	5
227	Hepatobiliary phase signal intensity: A potential method of diagnosing HCC with atypical imaging features among LR-M observations. <i>PLoS ONE</i> , 2021, 16, e0257308.	1.1	3
228	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	1.8	33
229	Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. <i>European Journal of Cancer</i> , 2021, 155, 85-96.	1.3	19
230	Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 147-154.	0.7	0
231	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1132-1143.	0.8	2
232	Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. <i>Frontiers in Oncology</i> , 2021, 11, 633033.	1.3	5
234	Therapeutic efficacy of a <i>Dioscorea membranacea</i> extract in a rat model of hepatocellular carcinoma: Histopathological aspects. <i>Journal of Traditional and Complementary Medicine</i> , 2021, 11, 400-408.	1.5	2
235	Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. <i>Cancer Reports</i> , 2022, 5, e1504.	0.6	3
236	Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective. <i>Cancers</i> , 2021, 13, 4732.	1.7	12
237	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
238	Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 6935-6941.	0.9	3
239	Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102782.	0.5	1
240	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100364.	2.6	9
241	Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. <i>European Journal of Surgical Oncology</i> , 2022, 48, 492-499.	0.5	21
242	YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. <i>Frontiers in Pharmacology</i> , 2021, 12, 744578.	1.6	13
243	Internet Search Trends Relevant to Interventional Oncology: A Google Trends Study (2004-2020). <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1445-1448.e1.	0.2	2
244	Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. <i>British Journal of Surgery</i> , 2021, 109, 71-78.	0.1	21

#	ARTICLE	IF	CITATIONS
246	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 271.	1.7	39
248	S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 114-126.	1.9	14
249	Regional liver function analysis with gadoteric acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC. <i>European Radiology</i> , 2021, 31, 4720-4730.	2.3	15
250	Multi-scale and multi-parametric radiomics of gadoteric acid-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm. <i>European Radiology</i> , 2021, 31, 4824-4838.	2.3	106
251	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 293-313.	8.2	428
252	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
253	Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 510-521.	4.2	23
254	Role of ellagic acid for the prevention and treatment of liver diseases. <i>Phytotherapy Research</i> , 2021, 35, 2925-2944.	2.8	23
255	The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1172-1183.	0.9	7
256	Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2021, 274, e1209-e1217.	2.1	45
257	Hepatocellular carcinoma: recent advances and emerging medical therapies. <i>F1000Research</i> , 2020, 9, 620.	0.8	41
258	Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. <i>Yeungnam University Journal of Medicine</i> , 2019, 36, 192-200.	0.7	4
259	Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. <i>World Journal of Clinical Cases</i> , 2019, 7, 2269-22286.	0.3	21
260	Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 2480-2505.	1.4	18
261	ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. <i>Annals of Translational Medicine</i> , 2019, 7, 691-691.	0.7	18
262	Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	4
263	Recent advances in unraveling the molecular mechanisms and functions of HOXA11-AS in human cancers and other diseases (Review). <i>Oncology Reports</i> , 2020, 43, 1737-1754.	1.2	19
264	Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. <i>Oncology Reviews</i> , 2020, 14, 515.	0.8	5

#	ARTICLE	IF	CITATIONS
265	Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 1553.	0.3	13
266	Novel molecular targets in hepatocellular carcinoma. <i>World Journal of Clinical Oncology</i> , 2020, 11, 589-605.	0.9	15
267	Predicting the coagulation volume induced by microwave ablation of hepatocellular carcinoma: the role of deposited energy, <i>ex-vivo</i> bovine liver charts and central hyperdense area on post-treatment CT. <i>International Journal of Hyperthermia</i> , 2021, 38, 1486-1494.	1.1	1
268	Liver radioembolization: historical essays and the first Russian results. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 5.	0.0	1
269	The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5096.	1.7	10
270	Diagnostik und Therapie des hepatozellulären Karzinoms. <i>Tumor Diagnostik Und Therapie</i> , 2021, 42, 562-574.	0.1	0
271	Radioablation of Upper Abdominal Malignancies by CT-Guided, Interstitial HDR Brachytherapy: A Multivariate Analysis of Catheter Placement Assisted by Ultrasound Imaging. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, 194, 62-69.	0.7	0
272	A New Prognostic Algorithm Predicting HCC Recurrence in Patients With Barcelona Clinic Liver Cancer Stage B Who Received PA-TACE. <i>Frontiers in Oncology</i> , 2021, 11, 742630.	1.3	10
273	Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. <i>BMC Gastroenterology</i> , 2021, 21, 393.	0.8	18
274	CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1851-1867.	0.9	46
275	Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. <i>Life</i> , 2021, 11, 1062.	1.1	0
277	The Synergistic Antitumor Effect of Combined Anti-Human Epidermal Growth Factor Receptor 2 Antibody and Gamma Interferon Therapy on Antibody-resistant Breast Cancer Cells. <i>The Showa University Journal of Medical Sciences</i> , 2019, 31, 237-252.	0.1	0
278	Second-line treatment of hepatocellular carcinoma: from theory to practical issues. <i>Meditinskiy Sovet</i> , 2019, , 30-36.	0.1	2
279	Liver Radioembolization: a New Chapter in Russian Oncology. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2019, 29, 7-12.	0.2	3
281	Liver Carcinoma. , 2020, , 131-143.		0
282	Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study. <i>Radiology and Oncology</i> , 2020, 54, 233-236.	0.6	3
283	Combined extensive liver resections in patients with locally advanced hepatocellular cancer – clinical cases. <i>IssledovaniĀ I Praktika V Medicine</i> , 2020, 7, 154-163.	0.1	0
284	Systemic therapy of hepatocellular carcinoma: reality and prospects. <i>Annals of HPB Surgery</i> , 2020, 25, 27-38.	0.1	2

#	ARTICLE	IF	CITATIONS
285	Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. <i>International Journal of Gastrointestinal Intervention</i> , 2021, 10, 183-188.	0.1	1
286	Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. <i>Hepatology Communications</i> , 2022, 6, 423-434.	2.0	5
287	Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	6
288	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , 2021, 101, 108322.	1.7	18
289	Hepatocellular carcinoma: update on treatment guidelines. <i>Gastrointestinal Nursing</i> , 2020, 18, S18-S26.	0.0	1
290	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. <i>Current Drug Metabolism</i> , 2020, 21, 866-884.	0.7	8
291	Prevention of hepatocellular carcinoma and surveillance of high risk patients. <i>Hepatology Forum</i> , 2021, , .	0.3	5
293	: Differentielle Indikationsstellung für Diagnostik in der Onkologie (Röntgen, CT, MRT, Sonografie). <i>Springer Reference Medizin</i> , 2020, , 1-19.	0.0	0
294	Experimental and Clinical Research Progress of Arsenic Trioxide in Treating Hepatocellular Carcinoma. <i>Traditional Chinese Medicine</i> , 2020, 09, 34-39.	0.1	0
295	Biopsy for hepatocellular carcinoma: only occasionally. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 666-667.	0.1	0
297	Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. <i>Cancers</i> , 2021, 13, 5558.	1.7	16
298	Transarterial Therapies for Benign and Malignant Liver Tumors. , 2021, , 153-179.		0
299	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. <i>Health Technology Assessment</i> , 2020, 24, 1-264.	1.3	4
300	Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part II. <i>Journal of Clinical Interventional Radiology ISVIR</i> , 2020, 4, 175-183.	0.0	0
301	Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?-the SCOOP-2 trial experience. <i>Annals of Translational Medicine</i> , 2020, 8, 1340.	0.7	0
302	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 2319-2330.	1.4	3
303	Evaluation of Hepatocellular Carcinoma Patients: Interim Analysis of Cases from a Tertiary Referral Center in Craiova, Romania. <i>Current Health Sciences Journal</i> , 2021, 47, 10-15.	0.2	0
304	Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 7172-7178.	0.0	2

#	ARTICLE	IF	CITATIONS
305	HepatozellulÄres Karzinom. , 2022, , 283-290.		0
306	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26
307	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
308	Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. <i>Immunotherapy</i> , 2021, , .	1.0	0
309	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12880.	1.8	15
310	Hepatocellular carcinoma in the non-cirrhotic liver. <i>Clinical Hemorheology and Microcirculation</i> , 2022, 80, 423-436.	0.9	10
311	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Caseâ€Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	2.0	28
312	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	1.7	13
313	Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoteric Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma. <i>Vestnik Rentgenologii I Radiologii</i> , 2021, 102, 284-295.	0.1	0
314	A national dose analysis of guided tumor destruction: influence of sex, age, localization and destruction technique used. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 12, 0-0.	1.1	0
315	Hepatocellular carcinoma with complete response to the immunotherapy: the oncologistâ€™s dilemma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	0.7	0
316	Microwave ablation versus laparoscopic resection as firstâ€line therapy for solitary 3â€5â€cm HCC. <i>Hepatology</i> , 2022, 76, 66-77.	3.6	40
317	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	1.3	8
318	Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e114-e120.	0.8	2
319	Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?â€”the SCOOP-2 trial experience. <i>Annals of Translational Medicine</i> , 2020, 8, 1340-1340.	0.7	2
320	The CRAFTY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy. <i>Journal of Hepatology</i> , 2022, 76, 1232-1233.	1.8	2
321	Yttrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. <i>Clinical and Translational Oncology</i> , 2022, 24, 796-808.	1.2	4
322	Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. <i>Medicine (United States)</i> , 2022, 101, e28545.	0.4	5

#	ARTICLE	IF	CITATIONS
323	A Hybrid Machine Learning Model Based on Semantic Information Can Optimize Treatment Decision for Na ⁺ -ve Single 3-5-cm HCC Patients. <i>Liver Cancer</i> , 2022, 11, 256-267.	4.2	3
324	Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2022, , .	0.9	3
325	Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 657512.	1.3	16
326	Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. <i>Liver Cancer</i> , 2022, 11, 219-232.	4.2	20
327	Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions. <i>Radiologia Medica</i> , 2022, 127, 129-144.	4.7	23
328	A hepatocellular carcinoma komplex kezelése. <i>Orvosi Hetilap</i> , 2022, 162, 2-31.	0.1	1
329	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	5.1	526
330	BCLC 2022 update: Important advances, but missing external beam radiotherapy. <i>Journal of Hepatology</i> , 2022, 76, 1237-1239.	1.8	9
332	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 149.	1.1	14
333	Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements. <i>Liver Cancer</i> , 2022, 11, 192-208.	4.2	20
334	Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. <i>EJNMMI Research</i> , 2022, 12, 9.	1.1	4
335	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	0.9	35
336	Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. <i>Journal of Hepatology</i> , 2022, 77, 219-236.	1.8	16
338	Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma. <i>Cancer Control</i> , 2022, 29, 107327482210768.	0.7	5
339	Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 909-925.	3.3	20
340	Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response. <i>Frontiers in Immunology</i> , 2022, 13, 847601.	2.2	18
342	Patient stratification in hepatocellular carcinoma: impact on choice of therapy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 297-306.	1.1	3
343	Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 809709.	1.3	13

#	ARTICLE	IF	CITATIONS
344	Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. <i>Annals of HPB Surgery</i> , 2022, 27, 33-39.	0.1	0
345	Scoring systems for the management of oncological hepato-pancreato-biliary patients. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, 17-30.	0.1	3
346	Multiple Light-Activated Photodynamic Therapy of Tetraphenylethylene Derivative with AIE Characteristics for Hepatocellular Carcinoma via Dual-Organelles Targeting. <i>Pharmaceutics</i> , 2022, 14, 459.	2.0	9
347	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 233-263.	1.8	27
348	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. <i>BMC Cancer</i> , 2022, 22, 293.	1.1	18
350	Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	0
351	Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Viruses</i> , 2022, 14, 656.	1.5	6
352	The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update. <i>Biomolecules</i> , 2022, 12, 462.	1.8	14
355	A clinical and pathological update on hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 14-22.	0.3	11
356	Mutational signatures and processes in hepatobiliary cancers. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 367-382.	8.2	2
357	A Novel Multimodal Radiomics Model for Predicting Prognosis of Resected Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 745258.	1.3	9
358	Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101923.	0.7	7
359	Clinical Outcome of CT-Guided Iodine-125 Radioactive Seed Implantation for Intrahepatic Recurrent Hepatocellular Carcinoma: A Retrospective, Multicenter Study. <i>Frontiers in Oncology</i> , 2022, 12, 819934.	1.3	1
360	Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. <i>European Radiology</i> , 2022, 32, 6493-6503.	2.3	5
361	Integrated analysis identified NPNT as a potential key regulator in tumor metastasis of hepatocellular carcinoma. <i>Gene</i> , 2022, 825, 146436.	1.0	6
362	Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study. <i>Cancer Reports</i> , 2022, 5, e1532.	0.6	5
363	Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2930-2942.	0.6	6
364	A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China. <i>Scientific Reports</i> , 2021, 11, 24353.	1.6	6

#	ARTICLE	IF	CITATIONS
365	Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. <i>Frontiers in Immunology</i> , 2021, 12, 792781.	2.2	39
366	Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5521-5532.	1.0	6
367	Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1896-1918.	0.8	5
368	Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. <i>World Journal of Gastroenterology</i> , 2021, 27, 8166-8181.	1.4	1
369	Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. <i>Cancers</i> , 2021, 13, 6310.	1.7	6
370	Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. 125Iodine Implantation. <i>Frontiers in Oncology</i> , 2021, 11, 806907.	1.3	14
372	Differential Diagnosis of Hepatic Mass with Central Scar: Focal Nodular Hyperplasia Mimicking Fibrolamellar Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 44.	1.3	1
373	The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. <i>Revista De Gastroenterología De México (English Edition)</i> , 2022, , .	0.1	1
374	Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 315-325.	1.8	5
380	Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. <i>Frontiers in Oncology</i> , 2022, 12, 839605.	1.3	8
381	Liver Transplantation in Hepatocellular Carcinoma: Experiences from the Shiraz Transplant Center.. <i>International Journal of Organ Transplantation Medicine</i> , 2021, 12, 9-19.	0.5	0
382	Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 811-833.	0.3	1
384	Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. <i>Clinical Epidemiology</i> , 2022, Volume 14, 581-590.	1.5	3
385	Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	4
386	Muscarinic Receptors Associated with Cancer. <i>Cancers</i> , 2022, 14, 2322.	1.7	8
387	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1110-1119.	1.0	19
388	Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. <i>RoFo Fortschritte Auf Dem Gebiet Der Röntgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, 194, 1075-1086.	0.7	7
389	Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. <i>Hepatology Research</i> , 2022, 52, 721-729.	1.8	21

#	ARTICLE	IF	CITATIONS
390	Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 389-403.	1.8	2
391	Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. Radiology and Oncology, 2022, 56, 311-318.	0.6	0
392	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	5.7	126
393	MR elastography is a good response parameter for microwave ablation liver tumors. European Journal of Radiology, 2022, , 110360.	1.2	1
394	A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm. Frontiers in Oncology, 2022, 12, .	1.3	7
396	Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study. Frontline Gastroenterology, 2023, 14, 19-24.	0.9	0
397	Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma. Frontiers in Endocrinology, 2022, 13, .	1.5	11
398	The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences. Journal of the National Cancer Center, 2022, 2, 171-182.	3.0	3
399	Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Meditsinskiy Sovet, 2022, , 31-39.	0.1	2
400	Cross Analysis of Genomic-Pathologic Features on Multiple Primary Hepatocellular Carcinoma. Frontiers in Genetics, 0, 13, .	1.1	1
401	Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. Liver Cancer, 2022, 11, 440-450.	4.2	22
402	Are all local tumour progressions of HCC related to thermal ablation? A study of the causes and classification of local tumour progression. European Radiology, 2022, 32, 8518-8526.	2.3	1
403	Single-session transarterial chemoembolization combined with percutaneous thermal ablation in liver metastases 3 cm or larger. Diagnostic and Interventional Imaging, 2022, 103, 516-523.	1.8	11
404	Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 670-681.	8.2	106
405	A Cancer-Pain Analgesia as Prolonging Strategy of Surviving Time after Failure of Adjuvant Chemotherapy in Patient with Progressive Bone-Metastatic Hepatocellular Carcinoma. Case Reports in Gastroenterology, 2022, 16, 394-399.	0.3	1
406	Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis. Updates in Surgery, 2022, 74, 1291-1297.	0.9	5
407	Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0â€“A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis. Hepatology International, 2022, 16, 892-905.	1.9	7
408	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	1.4	10

#	ARTICLE	IF	CITATIONS
409	Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis. <i>Ultrasound in Medicine and Biology</i> , 2022, , .	0.7	5
410	Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1278-1288.	0.6	3
411	Therapeutic Potential of Mitotic Kinases™ Inhibitors in Cancers of the Gastrointestinal System. <i>Future Pharmacology</i> , 2022, 2, 214-237.	0.6	3
412	The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. <i>Revista De Gastroenterología De México (English Edition)</i> , 2022, , .	0.1	0
413	Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1266-1277.	0.6	3
414	Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus-related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
415	Role of gadoteric acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment. <i>World Journal of Gastroenterology</i> , 2022, 28, 3116-3131.	1.4	0
416	DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biopsies. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
417	Clinical implications and biological features of a novel postoperative recurrent <sc>HCC</sc> classification: A multi-centre study. <i>Liver International</i> , 2022, 42, 2283-2298.	1.9	6
418	Prognostic factors of elderly patients with hepatocellular carcinoma: should we be more courageous in treatment?. <i>European Journal of Gastroenterology and Hepatology</i> , 0, Publish Ahead of Print, .	0.8	1
419	Present and future of target therapies and theranostics: refining traditions and exploring new frontiers highlights from annals of Nuclear Medicine 2021. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	3.3	2
420	Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	7
422	Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers. <i>Journal of Clinical Medicine</i> , 2022, 11, 4183.	1.0	2
423	How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
424	MELIF, a Fully Automated Liver Function Score Calculated from Gd-EOB-DTPA-Enhanced MR Images: Diagnostic Performance vs. the MELD Score. <i>Diagnostics</i> , 2022, 12, 1750.	1.3	1
425	Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. <i>BMJ Case Reports</i> , 2022, 15, e250009.	0.2	1
426	Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis. <i>Hepatology</i> , 2023, 77, 1929-1942.	3.6	5
427	Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. <i>Cancers</i> , 2022, 14, 3892.	1.7	1

#	ARTICLE	IF	CITATIONS
428	Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. <i>Liver Cancer</i> , 2023, 12, 44-56.	4.2	1
429	Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
430	Advances in novel systemic therapies for advanced hepatocellular carcinoma. <i>Future Medicinal Chemistry</i> , 0, , .	1.1	1
431	Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE). <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1430-1440.	0.9	15
433	Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. <i>Hepatology International</i> , 2022, 16, 1199-1207.	1.9	17
434	Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. <i>Cancer Medicine</i> , 2023, 12, 2572-2579.	1.3	5
435	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
436	A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
437	Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2022, 112, 109223.	1.7	7
438	Polypharmacology in Clinical Applicationsâ€”Anticancer Polypharmacology. , 2022, , 73-132.		0
439	Nonalcoholic steatohepatitis-induced hepatocellular carcinoma. , 2022, 7, 1.	0.1	0
440	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2023, 12, 116-128.	4.2	5
441	Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
442	Medicinal Plants in the Regulation of PD-L1/PD-1 Immune Checkpoint of Various Human Cancer Cells: A Narrative Review. <i>Current Cancer Therapy Reviews</i> , 2023, 19, 117-131.	0.2	0
443	A novel immune-related gene signature predicts the prognosis of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
444	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
447	Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
448	LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. <i>Cancers</i> , 2022, 14, 4584.	1.7	1

#	ARTICLE	IF	CITATIONS
449	Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β -catenin mutation in patients with hepatocellular carcinoma: A retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
450	Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors. <i>Cancer Medicine</i> , 2023, 12, 3046-3053.	1.3	2
451	Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
452	Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. <i>Liver Cancer</i> , 2023, 12, 72-84.	4.2	16
453	Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during COVID-19 pandemic. <i>Journal of Interventional Medicine</i> , 2022, , .	0.2	0
454	Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 1316-1333.	1.3	6
455	Spinal Cord Infarction After Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Korean Journal of Neurotrauma</i> , 2022, 18, 404.	0.2	1
456	Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas. <i>Cancers</i> , 2022, 14, 4807.	1.7	0
457	Imaging of Hepatocellular Carcinoma. <i>Updates in Surgery Series</i> , 2023, , 37-43.	0.0	0
458	Development and validation of a clinical radiomics model to predict recurrence for patients with hepatocellular carcinoma after curative resection. <i>Medical Physics</i> , 2023, 50, 778-790.	1.6	4
459	Endovascular Treatments of Hepatocellular Carcinoma. <i>Updates in Surgery Series</i> , 2023, , 71-79.	0.0	0
460	Repeated hepatic resection for colorectal liver metastases: is this concept safe and feasible?. <i>European Surgery - Acta Chirurgica Austriaca</i> , 0, , .	0.3	0
461	Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging. <i>Acta Radiologica</i> , 2023, 64, 1331-1340.	0.5	1
462	Magnetic Resonance-Guided Focused Ultrasound in the Treatment of Colorectal Cancer Liver Metastases. , 0, , .		2
463	Nanoscale CaO ₂ materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model. <i>Acta Biomaterialia</i> , 2022, 154, 536-548.	4.1	12
464	A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0276627.	1.1	0
465	Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. <i>Clinical and Experimental Metastasis</i> , 2023, 40, 5-32.	1.7	5
466	A rapid review of patient-reported outcomes investigated in the context of advanced renal cell cancer or advanced hepatocellular cancer. <i>European Journal of Oncology Nursing</i> , 2022, , 102241.	0.9	1

#	ARTICLE	IF	CITATIONS
467	Comparison of Two 2.45 GHz Microwave Ablation Devices with Respect to Ablation Zone Volume in Relation to Applied Energy in Patients with Malignant Liver Tumours. <i>Cancers</i> , 2022, 14, 5570.	1.7	3
468	Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene. , 2023, 40, .		0
469	Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2023, 4, 13-27.	0.2	0
470	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211173.	0.8	2
471	A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT). <i>Journal of Gastrointestinal Oncology</i> , 2022, .	0.6	0
472	Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04). <i>Cancers</i> , 2022, 14, 5848.	1.7	3
473	Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. , 2022, 10, e005457.		19
474	Preoperative differentiation of hepatocellular carcinoma with peripheral rim-like enhancement from intrahepatic mass-forming cholangiocarcinoma on contrast-enhanced MRI. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
475	Bridging and downstaging with <scp>TACE</scp> in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant. <i>Annals of Gastroenterological Surgery</i> , 0, , .	1.2	1
476	Identification and Validation of Glycosyltransferases Correlated with Cuproptosis as a Prognostic Model for Colon Adenocarcinoma. <i>Cells</i> , 2022, 11, 3728.	1.8	1
477	Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
478	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1434-1443.	0.8	50
479	Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments. <i>CardioVascular and Interventional Radiology</i> , 0, , .	0.9	1
480	A riskâ€based postâ€resection followâ€up strategy for hepatocellular carcinoma patients. <i>Cancer</i> , 0, , .	2.0	1
481	Prospective evaluation of low-dose multiphase hepatic computed tomography for detecting and characterizing hepatocellular carcinoma in patients with chronic liver disease. <i>BMC Medical Imaging</i> , 2022, 22, .	1.4	2
482	Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
483	Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and metaâ€analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	4
484	Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis. <i>Medicina (Lithuania)</i> , 2022, 58, 1859.	0.8	1

#	ARTICLE	IF	CITATIONS
485	Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5997.	1.7	7
486	Ó¼ÔµÔ;Ö€ÔÔ« Ô´Ô;Ô½Ô¶Ô;Ô°Ô;Ô¿Ô,Ô´Ô¶Ô¥Ô€Ô« Ô¢Ô;Ô€ÔÔ,Ô,Ô©ÔµÔ,Ô,Ô¶Ô¶Ô¥Ô€Ô´ Ô‡ Ô¶Ô€Ô;Ô¶Ô•Ô;Ô¶ÔÔ;Ô		
487	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Cancers</i> , 2023, 15, 50.	1.7	5
488	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. <i>Biomedicines</i> , 2022, 10, 3202.	1.4	26
489	SurvivalPath:A R package for conducting personalized survival path mapping based on time-series survival data. <i>PLoS Computational Biology</i> , 2023, 19, e1010830.	1.5	2
490	Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. <i>CardioVascular and Interventional Radiology</i> , 0, , .	0.9	0
491	Liver Cancer: Interdisciplinary Approach. , 2022, , 41-83.		0
492	Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1417.	1.8	10
493	CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
494	Thermal ablation of ultrasound and non-contrast CT invisible primary and secondary liver tumors: targeting by selective intra-arterial lipiodol injection. <i>Diagnostic and Interventional Radiology</i> , 2023, .	0.7	0
495	Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study. <i>Radiotherapy and Oncology</i> , 2023, 180, 109462.	0.3	4
496	A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making. <i>Annals of Translational Medicine</i> , 2023, 11, 68-68.	0.7	3
497	Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. <i>Cancers</i> , 2023, 15, 257.	1.7	11
498	Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	1
499	Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
500	Incidence and risk factors of cardiovascular mortality in patients with gastrointestinal adenocarcinoma. <i>PLoS ONE</i> , 2023, 18, e0262013.	1.1	1
501	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 230-241.	4.5	8
502	The diagnostic performance of radiomics-based MRI in predicting microvascular invasion in hepatocellular carcinoma: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
503	Lenvatinib <i>Versus</i> Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis. <i>Anticancer Research</i> , 2023, 43, 755-763.	0.5	2
504	Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 39-58.	0.4	1
505	Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules. <i>Brachytherapy</i> , 2023, , .	0.2	0
506	Radiation therapy in the era of immune treatment for hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
507	Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews. <i>Cancers</i> , 2023, 15, 766.	1.7	1
508	The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 949.	1.0	9
509	Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	2
510	CT-guided ¹²⁵ I brachytherapy for hepatocellular carcinoma in high-risk locations after transarterial chemoembolization combined with microwave ablation: a propensity score-matched study. <i>Radiology and Oncology</i> , 2023, 57, 127-139.	0.6	0
511	Raman scattering-based optical sensing of chronic liver diseases. <i>Photodiagnosis and Photodynamic Therapy</i> , 2023, 42, 103505.	1.3	1
512	Synthesis and biological evaluation of cholic acid-conjugated oxaliplatin as a new prodrug for liver cancer. <i>Journal of Inorganic Biochemistry</i> , 2023, 243, 112200.	1.5	4
513	Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2023, 70, 102365.	1.7	2
514	Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN- γ /NSDHL/SREBP1/TGF- β 1 axis in hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114254.	2.5	4
516	Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. <i>Cureus</i> , 2023, , .	0.2	1
517	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	19
518	Breakthroughs in Hepatocellular Carcinoma Therapies. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2135-2149.	2.4	20
519	Asia-Pacific multicentre randomized trial of laparoscopic <i>versus</i> open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial). <i>BJS Open</i> , 2023, 7, .	0.7	2
520	Liver cirrhosis and tumor location can affect the range of intrahepatic microwave ablation zone. <i>International Journal of Hyperthermia</i> , 2023, 40, .	1.1	1
521	Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2023, 32, 16-23.	0.2	1

#	ARTICLE	IF	CITATIONS
522	Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. <i>Cancer Treatment Reviews</i> , 2023, 115, 102526.	3.4	1
523	Evaluation of Electrochemotherapy with Bleomycin in the Treatment of Colorectal Hepatic Metastases in a Rat Model. <i>Cancers</i> , 2023, 15, 1598.	1.7	2
524	Sarcopenia negatively affects postoperative short-term outcomes of patients with non-cirrhosis liver cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
525	Effect of HBsAg expression in liver tissue on prognosis of hepatocellular carcinoma after minimally invasive interventional therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
526	Immunotherapy for advanced or recurrent hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 405-424.	0.8	0
527	Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. <i>World Journal of Gastroenterology</i> , 0, 29, 1669-1684.	1.4	0
528	CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE. <i>Current Oncology</i> , 2023, 30, 3516-3528.	0.9	2
529	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
531	Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma. <i>Abdominal Radiology</i> , 0, , .	1.0	0
532	Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2023, 58, 413-424.	2.3	10
533	Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. <i>Cancers</i> , 2023, 15, 2001.	1.7	5
534	Microwave Ablation of Recurrent Hepatocellular Carcinoma after Curative Surgical Resection. <i>Journal of Clinical Medicine</i> , 2023, 12, 2560.	1.0	2
535	Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 19, 329-339.	0.9	2
536	Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). <i>Liver Cancer</i> , 2023, 12, 405-444.	4.2	11
537	Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy. <i>Digestive and Liver Disease</i> , 2023, 55, 1288-1294.	0.4	2
539	Evaluation of the Clinical Efficacy of Intensity-Modulated Radiotherapy Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Extrahepatic Oligometastasis and Prognostic Factors for Patient Survival. <i>International Journal of General Medicine</i> , 0, Volume 16, 1271-1278.	0.8	1
540	Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study. <i>Hepatology International</i> , 2023, 17, 1251-1264.	1.9	2
576	Interventional Oncology Techniques: A Primer for Non-users. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
590	Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 780-798.	12.5	5
609	Transarterial Chemoembolization with Degradable Starch Microspheres (DSM-TACE). , 2023, , 65-76.		0
610	CBCT and Software. , 2023, , 31-37.		0
627	Radioembolization in the Treatment of Primary Liver Cancer. , 2023, , 1-19.		0
633	Liver Tumors. , 2023, , 473-480.		0
635	Large-scale data from real-life practice of percutaneous liver thermal ablation from an international registry: unconditionally trustful Atlas or colossus with feet of clay?. European Radiology, 0, , .	2.3	0
636	Automated Parameters Prediction for Microwave Thermal Ablation of Liver Tumor with Ultrasound Image. , 2023, , .		0